2lly
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
<StructureSection load='2lly' size='340' side='right' caption='[[2lly]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | <StructureSection load='2lly' size='340' side='right' caption='[[2lly]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | [[2lly]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LLY OCA]. <br> | + | <table><tr><td colspan='2'>[[2lly]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LLY OCA]. <br> |
| - | <b>[[Related_structure|Related:]]</b> [[2lm2|2lm2]]< | + | </td></tr><tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2lm2|2lm2]]</td></tr> |
| - | <b>Activity:</b> <span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span>< | + | <tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CHRNA4, NACRA4 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> |
| - | <b>Resources:</b> <span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2lly FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2lly OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2lly RCSB], [http://www.ebi.ac.uk/pdbsum/2lly PDBsum]</span>< | + | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr> |
| + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2lly FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2lly OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2lly RCSB], [http://www.ebi.ac.uk/pdbsum/2lly PDBsum]</span></td></tr> | ||
| + | <table> | ||
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/ACHA4_HUMAN ACHA4_HUMAN]] Autosomal dominant nocturnal frontal lobe epilepsy. The disease is caused by mutations affecting the gene represented in this entry. | [[http://www.uniprot.org/uniprot/ACHA4_HUMAN ACHA4_HUMAN]] Autosomal dominant nocturnal frontal lobe epilepsy. The disease is caused by mutations affecting the gene represented in this entry. | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/ACHA4_HUMAN ACHA4_HUMAN]] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.<ref>PMID:22361591</ref> | [[http://www.uniprot.org/uniprot/ACHA4_HUMAN ACHA4_HUMAN]] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.<ref>PMID:22361591</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
The alpha4beta2 nicotinic acetylcholine receptor (nAChR) is the predominant heteromeric subtype of nAChRs in the brain, which has been implicated in numerous neurological conditions. The structural information specifically for the alpha4beta2 and other neuronal nAChRs is presently limited. In this study, we determined structures of the transmembrane (TM) domains of the alpha4 and beta2 subunits in lauryldimethylamine-oxide (LDAO) micelles using solution NMR spectroscopy. NMR experiments and size exclusion chromatography-multi-angle light scattering (SEC-MALS) analysis demonstrated that the TM domains of alpha4 and beta2 interacted with each other and spontaneously formed pentameric assemblies in the LDAO micelles. The Na(+) flux assay revealed that alpha4beta2 formed Na(+) permeable channels in lipid vesicles. Efflux of Na(+) through the alpha4beta2 channels reduced intra-vesicle Sodium Green fluorescence in a time-dependent manner that was not observed in vesicles without incorporating alpha4beta2. The study provides structural insight into the TM domains of the alpha4beta2 nAChR. It offers a valuable structural framework for rationalizing extensive biochemical data collected previously on the alpha4beta2 nAChR and for designing new therapeutic modulators. | The alpha4beta2 nicotinic acetylcholine receptor (nAChR) is the predominant heteromeric subtype of nAChRs in the brain, which has been implicated in numerous neurological conditions. The structural information specifically for the alpha4beta2 and other neuronal nAChRs is presently limited. In this study, we determined structures of the transmembrane (TM) domains of the alpha4 and beta2 subunits in lauryldimethylamine-oxide (LDAO) micelles using solution NMR spectroscopy. NMR experiments and size exclusion chromatography-multi-angle light scattering (SEC-MALS) analysis demonstrated that the TM domains of alpha4 and beta2 interacted with each other and spontaneously formed pentameric assemblies in the LDAO micelles. The Na(+) flux assay revealed that alpha4beta2 formed Na(+) permeable channels in lipid vesicles. Efflux of Na(+) through the alpha4beta2 channels reduced intra-vesicle Sodium Green fluorescence in a time-dependent manner that was not observed in vesicles without incorporating alpha4beta2. The study provides structural insight into the TM domains of the alpha4beta2 nAChR. It offers a valuable structural framework for rationalizing extensive biochemical data collected previously on the alpha4beta2 nAChR and for designing new therapeutic modulators. | ||
| Line 16: | Line 19: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:45, 1 May 2014
NMR structures of the transmembrane domains of the nAChR a4 subunit
| |||||||||||
